StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva r&d expenses

Research and development expenses are spending on new products and technology.

Innoviva's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.20M, down 32.0% year over year. For fiscal 2025 it was $30.60M, up 124.1% from the year before. Over ten years it grew 27.9% a year on average. The highest annual figure on record is $103.57M in fiscal 2011.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.60M+124.1%
FY2024Dec 31, 2024$13.65M-59.7%
FY2023Dec 31, 2023$33.92M-18.1%
FY2022Dec 31, 2022$41.43M+7093.1%
FY2021Dec 31, 2021$576.00K-67.8%
FY2020Dec 31, 2020$1.79M–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0-100.0%
FY2017Dec 31, 2017$1.36M-2.7%
FY2016Dec 31, 2016$1.39M-46.8%
FY2015Dec 31, 2015$2.62M-65.1%
FY2014Dec 31, 2014$7.50M-17.0%
FY2013Dec 31, 2013$9.04M+10.9%
FY2012Dec 31, 2012$8.15M-92.1%
FY2011Dec 31, 2011$103.57M+38.0%
FY2010Dec 31, 2010$75.07M-3.2%
FY2009Dec 31, 2009$77.52M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$5.21M-61.9%
Q2 FY2026Jun 30, 2026$5.19M-35.0%
Q1 FY2026Mar 31, 2026$5.24M+19.2%
Q4 FY2025Dec 31, 2025$4.56M+24.3%
Q3 FY2025Sep 30, 2025$13.67M+285.0%
Q2 FY2025Jun 30, 2025$7.98M+211.8%
Q1 FY2025Mar 31, 2025$4.40M+13.4%
Q4 FY2024Dec 31, 2024$3.67M+55.6%
Q3 FY2024Sep 30, 2024$3.55M-11.0%
Q2 FY2024Jun 30, 2024$2.56M-82.9%
Q1 FY2024Mar 31, 2024$3.88M-69.2%
Q4 FY2023Dec 31, 2023$2.36M-76.4%
Q3 FY2023Sep 30, 2023$3.99M-66.0%
Q2 FY2023Jun 30, 2023$14.99M+8.0%
Q1 FY2023Mar 31, 2023$12.59M+115.6%
Q4 FY2022Dec 31, 2022$9.99M+24862.5%
Q3 FY2022Sep 30, 2022$11.73M+2511.4%
Q2 FY2022Jun 30, 2022$13.88M+36436.8%
Q1 FY2022Mar 31, 2022$5.84M+11814.3%
Q4 FY2021Dec 31, 2021$40.00K-81.7%
Q3 FY2021Sep 30, 2021$449.00K-55.5%
Q2 FY2021Jun 30, 2021$38.00K-93.2%
Q1 FY2021Mar 31, 2021$49.00K–
Q4 FY2020Dec 31, 2020$219.00K–
Q3 FY2020Sep 30, 2020$1.01M–
Q2 FY2020Jun 30, 2020$559.00K–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q4 FY2018Dec 31, 2018$0-100.0%
Q3 FY2018Sep 30, 2018$0-100.0%
Q2 FY2018Jun 30, 2018$0-100.0%
Q1 FY2018Mar 31, 2018$0-100.0%
Q4 FY2017Dec 31, 2017$342.00K-0.9%
Q3 FY2017Sep 30, 2017$311.00K–
Q2 FY2017Jun 30, 2017$348.00K–
Q1 FY2017Mar 31, 2017$354.00K–
Q4 FY2016Dec 31, 2016$345.00K–

More Innoviva figures

See a number that looks wrong?